EKSO Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -33.62% compared to Ekso Bionics Holdings, Inc.'s net margin of -12425.36%. Ekso Bionics Holdings, Inc.'s return on equity of -85.7% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Ekso Bionics Holdings, Inc. has a consensus price target of $9.50, signalling upside risk potential of 1.39%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.4167 which suggests that it could grow by 145.39%. Given that Perspective Therapeutics, Inc. has higher upside potential than Ekso Bionics Holdings, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Ekso Bionics Holdings, Inc..

Ekso Bionics Holdings, Inc. has a beta of 0.803, which suggesting that the stock is 19.673% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.747, suggesting its more volatile than the S&P 500 by 74.695%.

Ekso Bionics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ekso Bionics Holdings, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Ekso Bionics Holdings, Inc. quarterly revenues are $4.2M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Ekso Bionics Holdings, Inc.'s net income of -$1.4M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Ekso Bionics Holdings, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ekso Bionics Holdings, Inc. is 8.71x versus 343.09x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

InfuSystem Holdings, Inc. has a net margin of -33.62% compared to Ekso Bionics Holdings, Inc.'s net margin of 6.19%. Ekso Bionics Holdings, Inc.'s return on equity of -85.7% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.

Ekso Bionics Holdings, Inc. has a consensus price target of $9.50, signalling upside risk potential of 1.39%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 72.33%. Given that InfuSystem Holdings, Inc. has higher upside potential than Ekso Bionics Holdings, Inc., analysts believe InfuSystem Holdings, Inc. is more attractive than Ekso Bionics Holdings, Inc..

Ekso Bionics Holdings, Inc. has a beta of 0.803, which suggesting that the stock is 19.673% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.674, suggesting its more volatile than the S&P 500 by 67.352%.

Ekso Bionics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ekso Bionics Holdings, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.

Ekso Bionics Holdings, Inc. quarterly revenues are $4.2M, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Ekso Bionics Holdings, Inc.'s net income of -$1.4M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Ekso Bionics Holdings, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 31.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ekso Bionics Holdings, Inc. is 8.71x versus 1.24x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -33.62% compared to Ekso Bionics Holdings, Inc.'s net margin of -862.39%. Ekso Bionics Holdings, Inc.'s return on equity of -85.7% beat VolitionRX Ltd.'s return on equity of --.

Ekso Bionics Holdings, Inc. has a consensus price target of $9.50, signalling upside risk potential of 1.39%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 731.76%. Given that VolitionRX Ltd. has higher upside potential than Ekso Bionics Holdings, Inc., analysts believe VolitionRX Ltd. is more attractive than Ekso Bionics Holdings, Inc..

Ekso Bionics Holdings, Inc. has a beta of 0.803, which suggesting that the stock is 19.673% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.286, suggesting its more volatile than the S&P 500 by 28.569%.

Ekso Bionics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ekso Bionics Holdings, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Ekso Bionics Holdings, Inc. quarterly revenues are $4.2M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Ekso Bionics Holdings, Inc.'s net income of -$1.4M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Ekso Bionics Holdings, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ekso Bionics Holdings, Inc. is 8.71x versus 18.12x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -33.62% compared to Ekso Bionics Holdings, Inc.'s net margin of 3.93%. Ekso Bionics Holdings, Inc.'s return on equity of -85.7% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Ekso Bionics Holdings, Inc. has a consensus price target of $9.50, signalling upside risk potential of 1.39%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 149.58%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Ekso Bionics Holdings, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Ekso Bionics Holdings, Inc..

Ekso Bionics Holdings, Inc. has a beta of 0.803, which suggesting that the stock is 19.673% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.041, suggesting its less volatile than the S&P 500 by 104.125%.

Ekso Bionics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ekso Bionics Holdings, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Ekso Bionics Holdings, Inc. quarterly revenues are $4.2M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Ekso Bionics Holdings, Inc.'s net income of -$1.4M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Ekso Bionics Holdings, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 58.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ekso Bionics Holdings, Inc. is 8.71x versus 0.66x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.